Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biocryst Pharma Inc (NQ: BCRX )

7.600 +0.110 (+1.47%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biocryst Pharma Inc

< Previous 1 2 3 4 5 6 7 Next >
BioCryst Is On Fire: What Do Options Traders Expect Next?
Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) sur... 
Via Benzinga
60 Biggest Movers From Yesterday
Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares surged 57.1% to close at $5.39 on Monday. Zynga Inc. (NASDAQ: ZNGA) rose 40.7% to settle at $8.44 after the company... 
Via Benzinga
Biotech Bloodbath Continues Despite Gene-Editing Deals For Pfizer, Bayer
Pfizer and Bayer inked deals with several companies in gene-editing. 
Via Investor's Business Daily
Analyzing BioCryst Pharmaceuticals's Unusual Options Activity
BioCryst Pharmaceuticals (NASDAQ:BCRX) shares experienced... 
Via Benzinga
45 Stocks Moving In Monday's Mid-Day Session
Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares climbed 71.5% to $5.88. Zynga Inc. (NASDAQ: ZNGA) gained 45.7% to $8.74 after the company announced it will be acquired... 
Via Benzinga
3 Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, t... 
Via Benzinga
BioCryst Shares Gain As Royalty Pharma Buys Additional Interests In BCX9930, Orladeyo
Royalty Pharma plc (NASDAQ: RPRX) and OMERS Capital Markets have announced transactions worth $350 million in new funding in BioCryst Pharmaceuticals... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 10, 2021
Upgrades According to JP Morgan, the prior rating for Arconic Corp (NYSE: 
Via Benzinga
7 Top Growth Stocks to Buy as We Step Into November
Here are seven top growth stocks investors may want to consider when looking at options in this hyper-growth market right now. 
Via InvestorPlace
86 Biggest Movers From Yesterday
Gainers FAT Brands Inc. (NASDAQ: FATBB) shares gained 99.2% to settle at $15.44. FAT Brands recently announced plans to acquire Fazoli’s Restaurant Chain for $130 million.... 
Via Benzinga
BioCryst Pharmaceuticals (BCRX) Q3 2021 Earnings Call Transcript
BCRX earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Here's Why BioCryst Pharmaceuticals Stock Is Losing Ground Today
The biotech's third quarter was a good one, once you look past the top-line numbers. 
Via The Motley Fool
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers iRhythm Technologies (NASDAQ:IRTC) stock moved upwards by 52.78% to $117.34 during Wednesday's regular session. iRhythm Technologies's stock is trading at... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Glaukos (NYSE:GKOS) stock increased by 25.55% to $56.58 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.6 billion... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Tenet Healthcare (NYSE:THC) stock r... 
Via Benzinga
2 Super-Charged Growth Stocks to Buy Now
These two small drugmakers are poised for a long-winded growth spurt. 
Via The Motley Fool
NICE Recommends BioCryst's Hereditary Angioedema Med
The U.K.'s National Institute for Health and Care Excellence (NICE) has recommended BioCryst Pharmaceuticals Inc's (NASDAQ: BCRX) Orladeyo (berotralstat)... 
Via Benzinga
US Government Exercises Option To Buy Additional Doses Of BioCryst's Flu Med
The U.S. Department of Health and Human Services (HHS) has exercised its option to purchase an additional 10,000 doses of BioCryst Pharmaceuticals Inc's (... 
Via Benzinga
The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 25) Abbvie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures COVID-19
Analyzing BioCryst Pharmaceuticals's Unusual Options Activity
BioCryst Pharmaceuticals (NASDAQ:BCRX) shares experienced unusual options activity on Monday. The stock price moved down to $15.44 following the option alert. Sentiment: BULLISH... 
Via Benzinga
BioCryst Stock Jumps After Pulling Out $200M Equity Raise
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) has withdrawn its proposed public offering of $200 million of its stock and pre-funded warrants. The Company says... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers CohBar (NASDAQ:CWBR) stock moved upwards by 68.21% to $2.17 during Wednesday's pre-market session. The company's market cap stands at $134.0 million. The... 
Via Benzinga
22 Stocks Moving in Wednesday's Pre-Market Session
Gainers CohBar, Inc. (NASDAQ: CWBR) shares rose 78.3% to $2.30 in pre-market trading after the company reported results from the Phase 1a/1b study of CB4211 under development for... 
Via Benzinga
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,... 
Via Benzinga
Exposures Product Safety
85 Biggest Movers From Yesterday
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) jumped 125.3% to close at $18.77 on Tuesday after the company announced positive interim results from the Phase 1 trial with FTX... 
Via Benzinga
54 Stocks Moving In Tuesday's Mid-Day Session
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) climbed 79.3% to $14.93 after the company announced positive interim results from the Phase 1 trial with FTX-6058 in healthy... 
Via Benzinga
28 Stocks Moving in Tuesday's Pre-Market Session
Gainers Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) shares rose 38.6% to $66.88 in pre-market trading after the company reported better-than-expected Q2 earnings and also... 
Via Benzinga
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
BioCryst Pharmaceuticals (BCRX) Q2 2021 Earnings Call Transcript
BCRX earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Why BioCryst Pharmaceuticals Rose 8% on Thursday
The company's first commercial drug launch keeps exceeding expectations. 
Via The Motley Fool
Topics Earnings
Exposures Financial Product Safety
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.